Xiaoguang Li1, Wenbo Yao1, Ya Yuan1, Peizhan Chen1, Bin Li2, Jingquan Li1,3, Ruiai Chu1, Haiyun Song1,3, Dong Xie1,3,4, Xiaoqing Jiang2, Hui Wang1,3,4. 1. Key Laboratory of Food Safety Research, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China. 2. The Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China. 3. Key Laboratory of Food Safety Risk Assessment, Ministry of Health, Beijing, China. 4. School of Life Science and Technology, Shanghai Tech University, Shanghai, China.
Abstract
OBJECTIVE: Hepatocellular carcinoma (HCC) is an aggressive malignancy with limited effective treatment options. An alternative strategy is to target cells, such as tumour-infiltrating macrophages, in the HCC tumour microenvironment. The CCL2/CCR2 axis is required for recruitment of monocytes/macrophages and is implicated in various aspects of liver pathology, including HCC. We investigated the feasibility of CCL2/CCR2 as a therapeutic target against HCC. DESIGN: CCL2 expression was analysed in two independent HCC cohorts. Growth of three murine HCC cells was evaluated in an orthotopic model, a postsurgical recurrence model and a subcutaneous model in mice after blocking CCL2/CCR2 axis by a novel CCR2 antagonist or knocking out of host CCR2. In vivo macrophage or T cell depletion and in vitro cell coculture were further conducted to investigate CCL2/CCR2-mediated crosstalk between tumour-associated macrophages (TAMs) and tumour cells. RESULT: CCL2 is overexpressed in human liver cancers and is prognostic for patients with HCC. Blockade of CCL2/CCR2 signalling with knockout of CCR2 or with a CCR2 antagonist inhibits malignant growth and metastasis, reduces postsurgical recurrence, and enhances survival. Further, therapeutic blocking of the CCL2/CCR2 axis inhibits the recruitment of inflammatory monocytes, infiltration and M2-polarisation of TAMs, resulting in reversal of the immunosuppression status of the tumour microenvironment and activation of an antitumorous CD8+ T cell response. CONCLUSIONS: In patients with liver cancer, CCL2 is highly expressed and is a prognostic factor. Blockade of CCL2/CCR2 signalling suppresses murine liver tumour growth via activating T cell antitumour immune response. The results demonstrate the translational potential of CCL2/CCR2 blockade for treatment of HCCs. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
OBJECTIVE:Hepatocellular carcinoma (HCC) is an aggressive malignancy with limited effective treatment options. An alternative strategy is to target cells, such as tumour-infiltrating macrophages, in the HCC tumour microenvironment. The CCL2/CCR2 axis is required for recruitment of monocytes/macrophages and is implicated in various aspects of liver pathology, including HCC. We investigated the feasibility of CCL2/CCR2 as a therapeutic target against HCC. DESIGN:CCL2 expression was analysed in two independent HCC cohorts. Growth of three murine HCC cells was evaluated in an orthotopic model, a postsurgical recurrence model and a subcutaneous model in mice after blocking CCL2/CCR2 axis by a novel CCR2 antagonist or knocking out of host CCR2. In vivo macrophage or T cell depletion and in vitro cell coculture were further conducted to investigate CCL2/CCR2-mediated crosstalk between tumour-associated macrophages (TAMs) and tumour cells. RESULT: CCL2 is overexpressed in humanliver cancers and is prognostic for patients with HCC. Blockade of CCL2/CCR2 signalling with knockout of CCR2 or with a CCR2 antagonist inhibits malignant growth and metastasis, reduces postsurgical recurrence, and enhances survival. Further, therapeutic blocking of the CCL2/CCR2 axis inhibits the recruitment of inflammatory monocytes, infiltration and M2-polarisation of TAMs, resulting in reversal of the immunosuppression status of the tumour microenvironment and activation of an antitumorous CD8+ T cell response. CONCLUSIONS: In patients with liver cancer, CCL2 is highly expressed and is a prognostic factor. Blockade of CCL2/CCR2 signalling suppresses murineliver tumour growth via activating T cell antitumour immune response. The results demonstrate the translational potential of CCL2/CCR2 blockade for treatment of HCCs. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Entities:
Keywords:
CELL BIOLOGY; CHEMOKINES; HEPATOCELLULAR CARCINOMA; IMMUNOLOGY IN HEPATOLOGY; MACROPHAGES
Authors: Anusha Kalbasi; Chad Komar; Graham M Tooker; Mingen Liu; Jae W Lee; Whitney L Gladney; Edgar Ben-Josef; Gregory L Beatty Journal: Clin Cancer Res Date: 2016-06-28 Impact factor: 12.531
Authors: Richard L Bakst; Huizhong Xiong; Chun-Hao Chen; Sylvie Deborde; Anna Lyubchik; Yi Zhou; Shizhi He; William McNamara; Sei-Young Lee; Oakley C Olson; Ingrid M Leiner; Andrea R Marcadis; James W Keith; Hikmat A Al-Ahmadie; Nora Katabi; Ziv Gil; Efsevia Vakiani; Johanna A Joyce; Eric Pamer; Richard J Wong Journal: Cancer Res Date: 2017-09-26 Impact factor: 12.701
Authors: Kun-Yu Teng; Jianfeng Han; Xiaoli Zhang; Shu-Hao Hsu; Shun He; Nissar A Wani; Juan M Barajas; Linda A Snyder; Wendy L Frankel; Michael A Caligiuri; Samson T Jacob; Jianhua Yu; Kalpana Ghoshal Journal: Mol Cancer Ther Date: 2016-12-15 Impact factor: 6.261